220 related articles for article (PubMed ID: 24712435)
1. Abdominal attacks and treatment in hereditary angioedema with C1-inhibitor deficiency.
Rubinstein E; Stolz LE; Sheffer AL; Stevens C; Bousvaros A
BMC Gastroenterol; 2014 Apr; 14():71. PubMed ID: 24712435
[TBL] [Abstract][Full Text] [Related]
2. Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks.
Sheffer AL; MacGinnitie AJ; Campion M; Stolz LE; Pullman WE
Ann Allergy Asthma Immunol; 2013 Mar; 110(3):184-188.e2. PubMed ID: 23548529
[TBL] [Abstract][Full Text] [Related]
3. Analysis of hereditary angioedema attacks requiring a second dose of ecallantide.
Li HH; Campion M; Craig TJ; Soteres DF; Riedl M; Lumry WR; MacGinnitie AJ; Shea EP; Bernstein JA
Ann Allergy Asthma Immunol; 2013 Mar; 110(3):168-72. PubMed ID: 23548526
[TBL] [Abstract][Full Text] [Related]
4. Use of ecallantide in pediatric hereditary angioedema.
MacGinnitie AJ; Davis-Lorton M; Stolz LE; Tachdjian R
Pediatrics; 2013 Aug; 132(2):e490-7. PubMed ID: 23878046
[TBL] [Abstract][Full Text] [Related]
5. Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials.
Banta E; Horn P; Craig TJ
Allergy Asthma Proc; 2011; 32(4):319-24. PubMed ID: 21781409
[TBL] [Abstract][Full Text] [Related]
6. Ecallantide: in acute hereditary angioedema.
Garnock-Jones KP
Drugs; 2010 Jul; 70(11):1423-31. PubMed ID: 20614949
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ecallantide in treatment of recurrent attacks of hereditary angioedema: open-label continuation study.
Lumry WR; Bernstein JA; Li HH; MacGinnitie AJ; Riedl M; Soteres DF; Craig TJ; Campion M; Iarrobino R; Stolz LE; Pullman WE
Allergy Asthma Proc; 2013; 34(2):155-61. PubMed ID: 23484891
[TBL] [Abstract][Full Text] [Related]
8. Per-attack reporting of prodromal symptoms concurrent with C1-inhibitor treatment of hereditary angioedema attacks.
Prematta MJ; Bewtra AK; Levy RJ; Wasserman RL; Jacobson KW; Machnig T; Craig TJ
Adv Ther; 2012 Oct; 29(10):913-22. PubMed ID: 23054691
[TBL] [Abstract][Full Text] [Related]
9. Management of acute attacks of hereditary angioedema: role of ecallantide.
Duffey H; Firszt R
J Blood Med; 2015; 6():115-23. PubMed ID: 25931832
[TBL] [Abstract][Full Text] [Related]
10. Assessment of rebound and relapse following ecallantide treatment for acute attacks of hereditary angioedema.
Bernstein JA; Shea EP; Koester J; Iarrobino R; Pullman WE
Allergy; 2012 Sep; 67(9):1173-80. PubMed ID: 22765833
[TBL] [Abstract][Full Text] [Related]
11. Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics.
MacGinnitie AJ; Campion M; Stolz LE; Pullman WE
Allergy Asthma Proc; 2012; 33(2):178-85. PubMed ID: 22525395
[TBL] [Abstract][Full Text] [Related]
12. Ecallantide for treatment of acute attacks of acquired C1 esterase inhibitor deficiency.
Patel NS; Fung SM; Zanichelli A; Cicardi M; Cohn JR
Allergy Asthma Proc; 2013; 34(1):72-7. PubMed ID: 23406939
[TBL] [Abstract][Full Text] [Related]
13. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor.
Schneider L; Lumry W; Vegh A; Williams AH; Schmalbach T
J Allergy Clin Immunol; 2007 Aug; 120(2):416-22. PubMed ID: 17559913
[TBL] [Abstract][Full Text] [Related]
14. Clinical Pattern and Acute and Long-term Management of Hereditary Angioedema Due to C1-Esterase Inhibitor Deficiency.
Gómez-Traseira C; Pérez-Fernández E; López-Serrano MC; García-Ara MC; Pedrosa M; López-Trascasa M; Caballero T
J Investig Allergol Clin Immunol; 2015; 25(5):358-64. PubMed ID: 26727765
[TBL] [Abstract][Full Text] [Related]
15. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema.
Levy RJ; Lumry WR; McNeil DL; Li HH; Campion M; Horn PT; Pullman WE
Ann Allergy Asthma Immunol; 2010 Jun; 104(6):523-9. PubMed ID: 20568386
[TBL] [Abstract][Full Text] [Related]
16. Consider Hereditary Angioedema in the Differential Diagnosis for Unexplained Recurring Abdominal Pain.
Staller K; Lembo A; Banerji A; Bernstein JA; Shah ED; Riedl MA
J Clin Gastroenterol; 2022 Oct; 56(9):740-747. PubMed ID: 35960533
[TBL] [Abstract][Full Text] [Related]
17. Ecallantide for the treatment of hereditary angiodema in adults.
Lunn M; Banta E
Clin Med Insights Cardiol; 2011; 5():49-54. PubMed ID: 21695090
[TBL] [Abstract][Full Text] [Related]
18. Recurrent and acute abdominal pain as the main clinical manifestation in patients with hereditary angioedema.
Cao Y; Liu S; Zhi Y
Allergy Asthma Proc; 2021 Mar; 42(2):131-135. PubMed ID: 33685557
[No Abstract] [Full Text] [Related]
19. Sustained response of recombinant human C1 esterase inhibitor for acute treatment of hereditary angioedema attacks.
Bernstein JA; Relan A; Harper JR; Riedl M
Ann Allergy Asthma Immunol; 2017 Apr; 118(4):452-455. PubMed ID: 28284978
[TBL] [Abstract][Full Text] [Related]
20. Hereditary angioedema (HAE) in children and adolescents--a consensus on therapeutic strategies.
Wahn V; Aberer W; Eberl W; Faßhauer M; Kühne T; Kurnik K; Magerl M; Meyer-Olson D; Martinez-Saguer I; Späth P; Staubach-Renz P; Kreuz W
Eur J Pediatr; 2012 Sep; 171(9):1339-48. PubMed ID: 22543566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
